Sciclone Pharmaceuticals, Inc. (SCLN)

Sciclone Pharmaceuticals, Inc. is related to 4 other symbols. To date we've encountered 11 releases involving Sciclone Pharmaceuticals, Inc..

Last Price: 0.93 (+0.03) - 12/1/2008, 3:59pm

• Open: 0.83
• High: 0.94
• Low: 0.83

Sciclone Pharmaceuticals, Inc. Options

• Sciclone Pharmaceuticals, Inc. "Business Partners"
• Sciclone Pharmaceuticals, Inc. Press Releases
• Sciclone Pharmaceuticals, Inc. News
• Sciclone Pharmaceuticals, Inc. Contact
• Sciclone Pharmaceuticals, Inc. Related (via TRYNT)

Sciclone Pharmaceuticals, Inc. "Business Partners"

A "business partner" is defined as a third party company that has co-released at least one press release with Sciclone Pharmaceuticals, Inc..

• AVI
• MKGP
• PJC.A
• YGH

^

Sciclone Pharmaceuticals, Inc. Press Releases

• SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals to Present at the Rodman & Renshaw Healthcare Conference (Trackbacks) (Backlinks), Wed, 25 Oct 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the Rodman & Renshaw Healthcare Conference on Monday, November 6, 2006 at 12:50 pm EST.

• SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals to Report Third Quarter 2006 Results on October 31, 2006 (Trackbacks) (Backlinks), Thu, 19 Oct 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2006 results and host a conference call on Tuesday, October 31, 2006.

• SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals to Webcast Presentation at BIO InvestorForum Conference (Trackbacks) (Backlinks), Tue, 17 Oct 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview at the BIO InvestorForum 2006 Conference on Wednesday, October 18, 2006 at 2:20 p.m. PDT in San Francisco, California.

• SciClone Pharmaceuticals, Inc.: SciClone's New CEO Unveils Focused Global Strategic Vision (Trackbacks) (Backlinks), Mon, 25 Sep 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that Friedhelm Blobel, Ph.D., SciClone's recently appointed President and Chief Executive Officer, will unveil a focused global strategic vision and upcoming milestones during his presentation at the UBS Global Life Sciences Conference at 9:30 am EDT today. To access the live audio webcast of the presentation, log on through a link located in the

• SciClone Pharmaceuticals, Inc.: SciClone and Sigma-Tau Present Encouraging Interim Phase 2 Metastatic Malignant Melanoma Response Data (Trackbacks) (Backlinks), Mon, 18 Sep 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A today reported interim data showing that the addition of ZADAXIN(R) to standard dacarbazine (DTIC) chemotherapy, with or without interferon alpha in patients, with stage IV, the most advanced form of malignant melanoma, achieved double the overall tumor response as compared to the control group. Additional results from this trial, including

• SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference (Trackbacks) (Backlinks), Mon, 18 Sep 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the UBS Global Life Sciences Conference at the Grand Hyatt New York. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will deliver a corporate overview presentation on Monday, September 25, 2006 at 9:30 am EDT.

• SciClone Pharmaceuticals, Inc.: SciClone's SCV-07 Demonstrates Oral Bioavailability (Trackbacks) (Backlinks), Fri, 15 Sep 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported phase 1 data indicating that SCV-07 taken orally was safe and led to circulating plasma concentrations similar to those obtained in previous phase 1 studies using a subcutaneous injection of SCV-07. Importantly, SCV-07 taken orally resulted in only 10% plasma level variability between all volunteers in this study, demonstrating highly

• SciClone Pharmaceuticals, Inc.: SciClone to Report Second Quarter 2006 Results on August 1, 2006 (Trackbacks) (Backlinks), Tue, 11 Jul 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report second quarter 2006 results and host a conference call on Tuesday, August 1, 2006.

• SciClone Pharmaceuticals, Inc.: SciClone Acquires Exclusive Rights in China to DC Bead Chemoembolization Device (Trackbacks) (Backlinks), Thu, 8 Jun 2006 23:00:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has entered into a three year agreement with Biocompatibles International plc. (LSE: BII) granting SciClone exclusive rights to market Biocompatibles' DC BeadTM chemotherapy releasing device within China, particularly for the minimally invasive treatment of malignant hypervascular tumors such as primary liver cancer, hepatocellular

• SciClone Pharmaceuticals, Inc.: SciClone Announces Presentation of Pre-Clinical Data Showing Oral SCV-07 Efficacy Against Tuberculosis (Trackbacks) (Backlinks), Mon, 5 Jun 2006 3:30:00 PDT

  SAN MATEO, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the presentation of pre-clinical data demonstrating that SCV-07 in an oral formulation retains its immunomodulatory properties and is as effective as the standard injection formulation against tuberculosis (TB) in an animal model study. Alexander Kolobov, Ph.D. of Verta, Ltd. presented these data yesterday at the annual meeting of the Federation of

^

Sciclone Pharmaceuticals, Inc. News

• SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an (EDGAR Online), Thu, 20 Nov 2008 11:30:42 Etc/GMT
• SciClone Secures $6 Million in Debt Financing From Silicon Valley Bank (Marketwire), Wed, 19 Nov 2008 11:30:00 Etc/GMT
• SciClone Reaches Agreement With FDA on Special Protocol Assessment for Phase 3 Thymalfasin Trial in Stage IV Melanoma (Marketwire), Mon, 17 Nov 2008 11:30:00 Etc/GMT
• SCICLONE PHARMACEUTICALS INC Financials (EDGAR Online Financials), Thu, 13 Nov 2008 14:04:50 Etc/GMT
• New Star Analyst Rankings for SCICLONE PHARMA (StarMine), Sun, 9 Nov 2008 14:19:47 Etc/GMT
• SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition (EDGAR Online), Thu, 6 Nov 2008 18:15:00 Etc/GMT
• Q3 2008 SciClone Pharmaceuticals, Inc. Earnings Release - Time Not Supplied (CCBN), Thu, 6 Nov 2008 12:07:15 Etc/GMT
• SciClone Reports 52% Revenue Growth and a Profit in the Third Quarter of 2008 (Marketwire), Thu, 6 Nov 2008 11:30:00 Etc/GMT
• UPDATE - SciClone's hepatitis C drug fails main goal (at Reuters), Wed, 5 Nov 2008 21:21:14 Etc/GMT
• SciClone hepatitis C drug fails late-stage study (AP), Wed, 5 Nov 2008 13:14:16 Etc/GMT
• SciClone and Sigma-Tau Report Phase 3 Hepatitis C Trial Results (Marketwire), Wed, 5 Nov 2008 11:40:00 Etc/GMT
• SciClone Pharmaceuticals to Present at Rodman & Renshaw Global Investment Conference (Marketwire), Wed, 5 Nov 2008 11:30:00 Etc/GMT
• SciClone Pharmaceuticals to Report Third Quarter 2008 Results on November 6, 2008 (Marketwire), Mon, 27 Oct 2008 10:30:00 Etc/GMT
• SciClone Provides Promising Results From Its Phase 2A Clinical Trial Using SCV-07 as a Monotherapy in Patients With Chronic Hepatitis C Infection (Marketwire), Mon, 22 Sep 2008 10:30:00 Etc/GMT
• SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference (Marketwire), Tue, 16 Sep 2008 10:30:00 Etc/GMT
• Coverage initiated on SciClone Pharma by Susquehanna Financial (Briefing.com), Fri, 5 Sep 2008 13:10:26 Etc/GMT
• SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development (Marketwire), Thu, 7 Aug 2008 10:30:00 Etc/GMT
• SCICLONE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (EDGAR Online), Fri, 1 Aug 2008 21:23:20 Etc/GMT
• SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition (EDGAR Online), Tue, 29 Jul 2008 16:57:26 Etc/GMT
• SciClone Reports Results for the Second Quarter of 2008 (Marketwire), Tue, 29 Jul 2008 10:00:00 Etc/GMT

^

Sciclone Pharmaceuticals, Inc. Contact

• Corporate contact:
  Richard Waldron
  Chief Financial Officer
  SciClone Pharmaceuticals, Inc.
  650-358-3437
  
  

TRYNT Related

• TRYNT did not suggest any related symbols

^

What is a Stock Cloud?

A Stock Cloud is a tag cloud like display of stock ticker symbols. The larger the ticker symbol the more frequent that company distributes press releases.